Ray is now presenting Season Two of The Recommended Dose – produced by Cochrane Australia. The podcast is a series of intimate conversations with some of the world’s big thinkers in health, promoting a more questioning approach to healthcare.  Guests include BMJ’s editor in chief Dr Fiona Godlee, the extraordinary Professor John Ioannidis, brilliant British novelist Sarah Moss, JAMA Internal Medicine’s editor in chief Professor Rita Redberg, Australia’s leading health reporter, Dr Norman Swan, and many more. Your can listen to it here

Leading healthcare groups in Australia, including professional organisations, consumer groups and public bodies have endorsed an Initial Statement, on overdiagnosis. The statement acknowledges that the problem of too much medicine is harming people and threatening healthcare sustainability – taking resources away from areas of genuine need. The statement followed a National Summit on overdiagnosis held at the University of Sydney in July, facilitated by the Wiser Healthcare research collaboration.

Dr Ray Moynihan has won a prestigious fellowship from the National Health and Medical Research Council to examine the increasingly recognized problem of overdiagnosis. The research fellowship will have a focus on how disease definitions are expanding and in some cases labeling many people unnecessarily. He is undertaking the fellowship with colleagues at Bond University’s Centre for Research in Evidence-Based Practice, under the supervision of globally respected Professor Paul Glasziou.

The 5th international Preventing Overdiagnosis conference will be in Quebec City, Quebec, from August 17 to 19, 2017, hosted by the Quebec Medical Association. For more information and to submit an abstract or register see:  http://www.preventingoverdiagnosis.net/

A new paper published in the international open access scientific journal, PLOS ONE  reports on the results of community focus groups with Australia women – investigating views about overdiagnosis and low bone density, or osteoporosis.

A commentary published in January in the leading United States medical journal, JAMA Internal Medicine, calls for much greater transparency and independence between patient advocacy groups and the pharmaceutical industry.

A new study in early 2016, which interviewed British doctors, has some very interesting findings about their attitudes to the condition known as “Chronic Kidney Disease”.  The full text of the study, published in BMJ Open, is available here for free.

“CKD” was defined in 2002, and labels many people who will never experience any kidney disease. It is a good example of a controversial disease definition which is being questioned by doctors and others.

Extracts from the findings and discussion from the BMJ Open piece are here:

“The introduction of ‘CKD’ as a new disease construct conflicted with most GP professional values and personal understandings of general practice medicine.”

“I think when it first came in as an idea…we all rolled our eyes and went ‘Oh my God’, you know? They’re creating an illness that doesn’t exist.” (GPD)

“The inclusion of the words ‘chronic’ and ‘disease’ in the term CKD was also identified as a source of tension for clinicians.”

The 4th Preventing Overdiagnosis conference, which discusses studies like this one, is being held in Barcelona, September 20-22, 2016.